findmyKOL
Clinical trialNCT03295227RecruitingPhase 1Interventional

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

SponsorM.D. Anderson Cancer CenterEnrollment37Stage III Thymoma AJCC v8Stage IIIA Thymoma AJCC v8Stage IIIB Thymoma AJCC v8Stage IV Thymoma AJCC v8Stage IVA Thymoma AJCC v8Stage IVB Thymoma AJCC v8+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • M D Anderson Cancer Center

    Houston, Texas, United States

    Anne S. Tsao
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
6 Dec 2017
Primary completion
31 Dec 2027
Completion
31 Dec 2027
Last update posted
30 Jan 2026
Registered enrollment
37
Registry id
NCT03295227
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.